Javascript must be enabled to continue!
Pick a PACC: Comparing domain- specific- and general- cognitive composites in Alzheimer disease research
View through CrossRef
Balancing the evolution of longitudinal cognitive assessment with practical considerations like maintaining legacy measures presents a vexing problem for many Alzheimer's Disease Research Centers (ADRCs) in the US. Changes to the Uniform Data Set (UDS) have left many ADRCs with heterogeneous cognitive data that can be challenging to harmonize. Using longitudinal data from the Knight ADRC, we used equipercentile equating to combine cognitive data collected across UDS versions 2 and 3. The combined data was then used to assess whether equated variables could create stable and informative domain-specific and general cognitive composite measures. Exploratory factor analysis (EFA) revealed four underlying clusters of tests that corresponded to episodic memory, semantic memory, working memory, and attention/processing speed. These factors appeared stable across test forms, with equivalent factors observed when EFA was conducted on UDS2 and UDS3 independently, and replicated when UDS2 and UDS3 were harmonized using equated variables. To understand the utility of these domain-specific factors, we also computed a commonly used preclinical Alzheimer cognitive composite (ADCS-PACC), a novel PACC (Knight-PACC), and a global composite consisting of 13 cognitive tasks. Prior work has proposed that these PACCs are sensitive to preclinical changes in AD, while the global composite would reflect general cognitive ability. We compared the relationships between each composite and neuroimaging metrics of amyloid, tau, brain structure, and clinical symptoms, cross-sectionally and longitudinally. We also simulated clinical trials using each composite and compared the sample size estimates needed to power a study expecting to observe a moderate effect size. Overall, global and PACC-based metrics of cognition slightly outperformed domain-specific composites, showing better sensitivity to AD biomarkers, although the working memory composite consistently performed poorly. We also found that data-driven, domain-specific composites can complement already-established general cognitive composites, with the exception of the present working memory composite. Power analyses revealed that the global, Knight-PACC, and attention and processing speed composites would require the smallest sample sizes to detect cognitive change in a clinical trial, while the ADCS-PACC required two to three times as many participants. Importantly, this work demonstrated the stability of cognitive domains across test versions. Finally, in line with prior work, we also highlight that attention and processing speed may be sensitive metrics of cognitive change in the earliest stages of AD.
Title: Pick a PACC: Comparing domain- specific- and general- cognitive composites in Alzheimer disease research
Description:
Balancing the evolution of longitudinal cognitive assessment with practical considerations like maintaining legacy measures presents a vexing problem for many Alzheimer's Disease Research Centers (ADRCs) in the US.
Changes to the Uniform Data Set (UDS) have left many ADRCs with heterogeneous cognitive data that can be challenging to harmonize.
Using longitudinal data from the Knight ADRC, we used equipercentile equating to combine cognitive data collected across UDS versions 2 and 3.
The combined data was then used to assess whether equated variables could create stable and informative domain-specific and general cognitive composite measures.
Exploratory factor analysis (EFA) revealed four underlying clusters of tests that corresponded to episodic memory, semantic memory, working memory, and attention/processing speed.
These factors appeared stable across test forms, with equivalent factors observed when EFA was conducted on UDS2 and UDS3 independently, and replicated when UDS2 and UDS3 were harmonized using equated variables.
To understand the utility of these domain-specific factors, we also computed a commonly used preclinical Alzheimer cognitive composite (ADCS-PACC), a novel PACC (Knight-PACC), and a global composite consisting of 13 cognitive tasks.
Prior work has proposed that these PACCs are sensitive to preclinical changes in AD, while the global composite would reflect general cognitive ability.
We compared the relationships between each composite and neuroimaging metrics of amyloid, tau, brain structure, and clinical symptoms, cross-sectionally and longitudinally.
We also simulated clinical trials using each composite and compared the sample size estimates needed to power a study expecting to observe a moderate effect size.
Overall, global and PACC-based metrics of cognition slightly outperformed domain-specific composites, showing better sensitivity to AD biomarkers, although the working memory composite consistently performed poorly.
We also found that data-driven, domain-specific composites can complement already-established general cognitive composites, with the exception of the present working memory composite.
Power analyses revealed that the global, Knight-PACC, and attention and processing speed composites would require the smallest sample sizes to detect cognitive change in a clinical trial, while the ADCS-PACC required two to three times as many participants.
Importantly, this work demonstrated the stability of cognitive domains across test versions.
Finally, in line with prior work, we also highlight that attention and processing speed may be sensitive metrics of cognitive change in the earliest stages of AD.
Related Results
Abstract 5988: A non-canonical CDK9 complex mediates endocycling in polyaneuploid cancer cell (PACC) state
Abstract 5988: A non-canonical CDK9 complex mediates endocycling in polyaneuploid cancer cell (PACC) state
Abstract
Once prostate cancer has spread from its primary site, treatment is limited to systemically administered therapy. While tumors initially respond to these th...
Feasibility study of assessing the Preclinical Alzheimer Cognitive Composite (PACC) score via videoconferencing
Feasibility study of assessing the Preclinical Alzheimer Cognitive Composite (PACC) score via videoconferencing
Abstract
Background
The Preclinical Alzheimer Cognitive Composite (PACC) is a composite score which can detect the first signs of cognitive impairme...
Abstract 1795: Molecular vulnerabilities of the polyaneuploid cancer cell state
Abstract 1795: Molecular vulnerabilities of the polyaneuploid cancer cell state
Abstract
Once cancer has metastasized it remains incurable owing to resistance to nearly all systemic therapies. Classical views of therapeutic resistance include tu...
Optimal Weighting of Preclinical Alzheimer’s Cognitive Composite (PACC) Scales to Improve their Performance as Outcome Measures for Alzheimer’s Disease Clinical Trials
Optimal Weighting of Preclinical Alzheimer’s Cognitive Composite (PACC) Scales to Improve their Performance as Outcome Measures for Alzheimer’s Disease Clinical Trials
Introduction: Cognitive composite scales constructed by combining existing neuropsychometric tests are seeing wide application as endpoints for clinical trials and cohort studies o...
Penerapan Metode Convolutional Neural Network untuk Diagnosa Penyakit Alzheimer
Penerapan Metode Convolutional Neural Network untuk Diagnosa Penyakit Alzheimer
Abstract— Alzheimer's disease is a neurodegenerative disease that develops gradually, and is associated with cardiovascular and cerebrovascular problems. Alzheimer's is a serious d...
The role of chemotherapy in the management of pancreatic acinar cell carcinoma
The role of chemotherapy in the management of pancreatic acinar cell carcinoma
AbstractIntroductionPancreatic acinar cell carcinoma (pACC) is a rare malignancy with unique clinical and molecular features. The role of chemotherapy in pACC management is not wel...
Clinical characteristics and biomarker profile in early- and late-onset Alzheimer’s disease: the Shanghai Memory Study
Clinical characteristics and biomarker profile in early- and late-onset Alzheimer’s disease: the Shanghai Memory Study
Abstract
Early-onset Alzheimer’s disease constitutes ∼5–10% of Alzheimer’s disease. Its clinical characteristics and biomarker profiles are not well documented. To c...
Race, polygenic risk and their association with incident dementia among older US adults
Race, polygenic risk and their association with incident dementia among older US adults
AbstractDementia incidence increases steadily with age at rates that may vary across racial groups. This racial disparity may be attributable to polygenic risk, as well as lifestyl...

